JP2013511534A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511534A5 JP2013511534A5 JP2012540047A JP2012540047A JP2013511534A5 JP 2013511534 A5 JP2013511534 A5 JP 2013511534A5 JP 2012540047 A JP2012540047 A JP 2012540047A JP 2012540047 A JP2012540047 A JP 2012540047A JP 2013511534 A5 JP2013511534 A5 JP 2013511534A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- medicament
- psoriasis
- brimonidine
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 12
- 210000003491 Skin Anatomy 0.000 claims 4
- 201000004681 psoriasis Diseases 0.000 claims 4
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 3
- 229960003679 brimonidine Drugs 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 239000002674 ointment Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 229960001631 Carbomer Drugs 0.000 claims 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 1
- 239000004909 Moisturizer Substances 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 mists Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920001888 polyacrylic acid Polymers 0.000 claims 1
- 230000002335 preservative Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (11)
- 対象の乾癬またはそれに伴う症状を治療または予防する薬剤を製造するための、治療上有効な量のブリモニジンおよび医薬品として許容される担体の使用であって、薬剤が、乾癬またはそれに伴う症状に罹患しているまたは罹患し易い対象の皮膚領域への局所投与のためのものである使用。
- 薬剤が、ブリモニジンを0.01重量%から5重量%含む、請求項1に記載の使用。
- 薬剤が、ブリモニジンを0.05〜0.5重量%、0.07〜0.7重量%、または0.1〜0.6重量%含む、請求項2に記載の使用。
- 薬剤が、約0.1g/cm2から約5g/cm2皮膚領域で、1日当たり1から4回の施用で皮膚領域に投与される、請求項2に記載の使用。
- 対象に、乾癬またはそれに伴う症状のための少なくとも1種の治療薬および薬剤がさらに投与される、請求項1に記載の使用。
- 薬剤が二酸化チタンをさらに含む、請求項1に記載の使用。
- 薬剤が、スプレー、ミスト、エアロゾル、溶液、ローション、ゲル、クリーム、軟膏、ペースト、軟膏剤、エマルジョン、および懸濁液からなる群から選択される形態である、請求項1に記載の使用。
- 薬剤が、水と、水でゲル化する量のカルボマー、ポリアクリル酸グリセリン、およびこれらの混合物からなる群から選択される医薬品として許容されるゲル化剤とを含む、水性ゲルを含み、薬剤が、生理学的に許容されるpHを有する、請求項1に記載の使用。
- 薬剤が、クリームおよび軟膏の少なくとも1種を含み、それぞれが、ステアリン酸、ステアリルアルコール、セチルアルコール、グリセリン、水、およびこれらの混合物からなる群から選択される作用物質を含んでおり、薬剤は、生理学的に許容されるpHを有する、請求項1に記載の使用。
- 薬剤が、乾癬またはそれに伴う症状を治療または予防するための少なくとも1種の追加の医薬品活性成分をさらに含む、請求項1に記載の使用。
- 薬剤が、保存料、局所麻酔薬、および皮膚保湿剤をさらに含む、請求項1に記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/621,942 US8394800B2 (en) | 2009-11-19 | 2009-11-19 | Method for treating psoriasis |
| US12/621,942 | 2009-11-19 | ||
| PCT/US2010/057184 WO2011075267A1 (en) | 2009-11-19 | 2010-11-18 | Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013511534A JP2013511534A (ja) | 2013-04-04 |
| JP2013511534A5 true JP2013511534A5 (ja) | 2013-06-27 |
| JP5680660B2 JP5680660B2 (ja) | 2015-03-04 |
Family
ID=43729952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540047A Expired - Fee Related JP5680660B2 (ja) | 2009-11-19 | 2010-11-18 | 乾癬を治療または予防するためのα２アドレナリン受容体作動薬の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8394800B2 (ja) |
| EP (1) | EP2501373B1 (ja) |
| JP (1) | JP5680660B2 (ja) |
| KR (2) | KR20130106439A (ja) |
| CN (1) | CN102844025B (ja) |
| AU (1) | AU2010332233C1 (ja) |
| BR (1) | BR112012012131A2 (ja) |
| CA (1) | CA2781112C (ja) |
| ES (1) | ES2532527T3 (ja) |
| HK (1) | HK1175698A1 (ja) |
| MX (1) | MX2012005790A (ja) |
| NZ (1) | NZ600333A (ja) |
| RU (1) | RU2538729C2 (ja) |
| WO (1) | WO2011075267A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| KR20130010122A (ko) | 2010-03-26 | 2013-01-25 | 갈데르마 리써어치 앤드 디벨로프먼트 | 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물 |
| BR112012024289A2 (pt) | 2010-03-26 | 2017-07-18 | Galderma Res & Dev | "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica" |
| US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| ES2498217T5 (es) | 2010-10-21 | 2018-03-19 | Galderma S.A. | Composición en forma de gel basada en brimonidina |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| FR2977493B1 (fr) * | 2011-07-05 | 2014-02-14 | Galderma Res & Dev | Nouvelle composition anesthesique stable pour la reduction des reactions cutanees |
| WO2013016072A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| US9861645B2 (en) | 2012-12-28 | 2018-01-09 | Rak Holdings Llc | Anti-itch scalp treatment compositions and combinations |
| US20140350106A1 (en) * | 2013-05-22 | 2014-11-27 | Professional Compounding Centers Of America | Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same |
| KR20160037791A (ko) * | 2014-09-29 | 2016-04-06 | (주)네오팜 | 건성 치료용 산성 외용제 조성물 |
| JP7534795B2 (ja) | 2019-05-01 | 2024-08-15 | クレキシオ バイオサイエンシーズ エルティーディー． | そう痒症を治療する方法 |
| US20220211672A1 (en) * | 2019-05-01 | 2022-07-07 | Clexio Biosciences Ltd. | Methods of treating pruritus |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| US3560501A (en) | 1966-09-15 | 1971-02-02 | Ciba Geigy Corp | Process for making dihydroquinazolines |
| US3723432A (en) | 1968-11-12 | 1973-03-27 | Sandoz Ag | 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation |
| US3594380A (en) | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
| BE766039A (fr) | 1971-04-21 | 1971-09-16 | Labofina Sa | Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres. |
| US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
| US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US4164570A (en) | 1973-09-24 | 1979-08-14 | David Clough | Stabilized aqueous catecholamine solutions |
| US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| US4285967A (en) | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
| US4256763A (en) | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| IL92351A (en) | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt |
| FR2648709A1 (fr) | 1989-06-23 | 1990-12-28 | Boehringer Ingelheim France | Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants |
| US5198442A (en) | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5077292A (en) | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
| US5326763A (en) | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5204347A (en) | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
| US5112822A (en) | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5021416A (en) | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
| US5130441A (en) | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5237072A (en) | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| ES2187533T3 (es) | 1993-10-13 | 2003-06-16 | Allergan Inc | Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina. |
| US6323204B1 (en) | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
| WO1996013267A2 (en) | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
| US5693647A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| WO1996025163A1 (en) | 1995-02-14 | 1996-08-22 | Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center | Treatment of herpes simplex viruses |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5720962A (en) | 1995-10-04 | 1998-02-24 | Au Pharmaceuticals, Inc. | Analgesic lotion for hemorrhoids and method of making such lotion |
| US6441047B2 (en) | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
| US5916574A (en) | 1996-10-09 | 1999-06-29 | Ideal Ideas, Inc. | Method of treating natural poison skin conditions |
| US5753637A (en) | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
| EP0969790A2 (de) | 1997-02-21 | 2000-01-12 | Beiersdorf Aktiengesellschaft | Zubereitungen für die behandlung von rosacea |
| US6159944A (en) | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
| DE99907899T1 (de) * | 1998-03-11 | 2005-01-13 | Kabushiki Kaisha Soken | Hautnormalisierungsmittel |
| US6432934B1 (en) | 1998-08-06 | 2002-08-13 | Advanced Vision Research | Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease |
| US20030087962A1 (en) | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
| US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
| WO2000076502A1 (en) | 1999-06-11 | 2000-12-21 | The Ohio State University Research Foundation | Methods and compositions for treating raynaud's phenomenon and scleroderma |
| US6147102A (en) | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
| US20030077301A1 (en) | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
| US6294553B1 (en) | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
| US6284765B1 (en) | 2000-04-27 | 2001-09-04 | The University Of North Texas Health Science Center At Fort Worth | (+) naloxone and epinephrine combination therapy |
| US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| AU2002256471B2 (en) | 2001-05-03 | 2007-05-24 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
| US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| US20040092482A1 (en) | 2002-11-07 | 2004-05-13 | Gupta Shyam K. | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions |
| US20040156873A1 (en) | 2003-02-10 | 2004-08-12 | Gupta Shyam K. | Topically Bioavailable Acne and Rosacea Treatment Compositions |
| US20040220259A1 (en) | 2003-04-04 | 2004-11-04 | Yu Ruey J. | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels |
| WO2004103233A1 (en) | 2003-05-15 | 2004-12-02 | Cutanix Corporation | Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050059664A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
| US7141597B2 (en) * | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
| US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| KR20060126448A (ko) | 2003-09-12 | 2006-12-07 | 알러간, 인코포레이티드 | 통증 및 다른 알파 2 아드레날린 매개 증상을 치료하기위한 방법 및 조성물 |
| US7285544B2 (en) * | 2003-11-18 | 2007-10-23 | Bernstein Eric F | Use of nitroxides in treating skin disease |
| US7239705B2 (en) | 2003-12-10 | 2007-07-03 | Motorola Inc. | Apparatus and method for broadcast services transmission and reception |
| US20050238705A1 (en) * | 2004-01-14 | 2005-10-27 | Ning Hu | Lipid-based dispersions useful for drug delivery |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| JP4955543B2 (ja) * | 2004-05-25 | 2012-06-20 | サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド | 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法 |
| US8158161B2 (en) * | 2005-01-12 | 2012-04-17 | S.U.L.V.E. Ltd. | Methods and pharmaceutical compositions useful for treating psoriasis |
| US20070082070A1 (en) | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
| MX2008011236A (es) | 2006-03-01 | 2009-02-10 | Tristrata Inc | Composicion y metodo para tratamiento topico de trastornos dermatologicos que responden a alquitran. |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| JP2011512345A (ja) * | 2008-02-15 | 2011-04-21 | ボーン・セラピューティクス | 骨関節疾患の治療及び／または予防において使用する医薬組成物 |
| AU2009214044B2 (en) * | 2008-02-15 | 2014-08-14 | Bone Therapeutics | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases |
| EP2090307A1 (en) | 2008-02-15 | 2009-08-19 | Bone Therapeutics | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
-
2009
- 2009-11-19 US US12/621,942 patent/US8394800B2/en not_active Expired - Fee Related
-
2010
- 2010-11-18 CN CN201080051989.9A patent/CN102844025B/zh not_active Expired - Fee Related
- 2010-11-18 EP EP10779906.6A patent/EP2501373B1/en not_active Not-in-force
- 2010-11-18 AU AU2010332233A patent/AU2010332233C1/en not_active Ceased
- 2010-11-18 WO PCT/US2010/057184 patent/WO2011075267A1/en active Application Filing
- 2010-11-18 JP JP2012540047A patent/JP5680660B2/ja not_active Expired - Fee Related
- 2010-11-18 MX MX2012005790A patent/MX2012005790A/es active IP Right Grant
- 2010-11-18 CA CA2781112A patent/CA2781112C/en not_active Expired - Fee Related
- 2010-11-18 NZ NZ600333A patent/NZ600333A/en not_active IP Right Cessation
- 2010-11-18 ES ES10779906.6T patent/ES2532527T3/es active Active
- 2010-11-18 RU RU2012125249/15A patent/RU2538729C2/ru not_active IP Right Cessation
- 2010-11-18 KR KR1020137021672A patent/KR20130106439A/ko not_active Application Discontinuation
- 2010-11-18 BR BR112012012131A patent/BR112012012131A2/pt not_active IP Right Cessation
- 2010-11-18 KR KR1020127015875A patent/KR101374907B1/ko not_active IP Right Cessation
-
2013
- 2013-03-05 US US13/785,802 patent/US9072739B2/en not_active Expired - Fee Related
- 2013-03-07 HK HK13102850.0A patent/HK1175698A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013511534A5 (ja) | ||
| ES2368974T3 (es) | Preparación que contiene osmolitos para uso en caso de membranas mucosas secas. | |
| JP2668800B2 (ja) | 皮膚疾患の局所治療 | |
| KR102153457B1 (ko) | 다한증 치료용 항콜린성 글리코피롤레이트 에스테르 | |
| US20080031979A1 (en) | Use of extracts for the treatment of viral disorders | |
| US20120264818A1 (en) | Topical Compositions with Cannabis Extracts | |
| JP2010537988A5 (ja) | ||
| US20130072532A1 (en) | Topical transdermal dexmedetomidine compositions and methods of use thereof | |
| JP2009280627A5 (ja) | ||
| KR102587297B1 (ko) | 수면장애 예방 또는 치료용 조성물 | |
| JP2011529038A5 (ja) | ||
| WO2009053741A3 (en) | Novel formulation | |
| WO2018175796A1 (en) | Skin care compositions and methods | |
| US20130274321A1 (en) | Topical Compositions with Cannabis Extracts | |
| US20190105335A1 (en) | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort | |
| CN107670027B (zh) | 治疗皮肤病况的组合物和方法 | |
| JP5179352B2 (ja) | ウイルス性障害の治療のためのカルコン類の使用 | |
| JP2016517882A5 (ja) | ||
| ES2551614T3 (es) | Uso de alcoholes pegilados para el tratamiento de la queratosis actínica | |
| WO2005037275A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| ITUB20159582A1 (it) | Composizione, per uso topico, utile per la prevenzione di disturbi di tipo infiammatorio e/o infettivo delle mucose. | |
| RU2011121659A (ru) | Депигментирующие местные композиции и их применение | |
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| JP2004262775A5 (ja) | ||
| JP5980488B2 (ja) | 口角炎の治療用医薬組成物 |